| 货号 | HC336016 |
|---|---|
| 品牌 | abinScience |
| 种属反应性 | Human |
| 应用 | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
| 宿主 | Human |
| 同种型 | IgG2-lambda |
| 表达系统 | Mammalian Cells |
| 克隆类型 | Monoclonal |
| 靶标 | Tumor necrosis factor receptor superfamily member 9, CD137, 4-1BB ligand receptor, CDw137, TNFRSF9, T-cell antigen ILA, T-cell antigen 4-1BB homolog, ILA |
| 内毒素水平 | Please contact the lab for this information. |
| 纯度 | >95% purity as determined by SDS-PAGE. |
| 纯化方式 | Protein A/G purified from cell culture supernatant. |
| Accession号 | Q07011 |
| 状态 | Liquid |
| 保存溶液 | 0.01M PBS, pH 7.4. |
| 稳定性和存储 | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
| 别名 | PF-05082566, PF-2566, 1417318-27-4 |
| 背景 | Urelumab is a fully humanized agonistic monoclonal antibody targeting the CD137 receptor with potential immunostimulatory and antineoplastic activities. Urelumab specifically binds to and activates CD137-expressing immune cells, stimulating an immune response, in particular a cytotoxic T cell response, against tumor cells. Urelumab has been used in trials studying the treatment of Leukemia, Multiple Myeloma, Malignant Tumors, and Cancer-Solid Tumors and B-Cell Non-Hodgkin's Lymphoma. The antibody product was developed using Medarex's UltiMAb(R) technology and was the first UltiMAb-derived antibody in clinical development by Bristol-Myers Squibb under the December 2003 agreement with Medarex. In December 2008, enrolment was stopped for all urelumab studies following the occurrence of two hepatotoxicity-related deaths. Several years later, the clinical study on Urelumab was restarted. At present, the approval of the monoclonal antibody has not been disclosed in the relevant drug approval agency. • Analysis of 4-1BBL and laminin binding to murine 4-1BB, a member of the tumor necrosis factor receptor superfamily, and comparison with human 4-1BB., PMID:9045669 • ILA, the human 4-1BB homologue, is inducible in lymphoid and other cell lineages., PMID:7849293 • CD137 (ILA/4-1BB), expressed by primary human monocytes, induces monocyte activation and apoptosis of B lymphocytes., PMID:10607752 • CD137 (ILA/4-1BB), a member of the TNF receptor family, induces monocyte activation via bidirectional signaling., PMID:9498794 • A soluble form of CD137 (ILA/4-1BB), a member of the TNF receptor family, is released by activated lymphocytes and is detectable in sera of patients with rheumatoid arthritis., PMID:9485208 • CD137-induced apoptosis is independent of CD95., PMID:10469232 • CD137 activation abrogates granulocyte-macrophage colony-stimulating factor-mediated anti-apoptosis in neutrophils., PMID:11093162 • Expression of CD137 and its ligand in human neurons, astrocytes, and microglia: modulation by FGF-2., PMID:13130507 • Comparative analysis of CD137 and LPS effects on monocyte activation, survival, and proliferation., PMID:10873573 • CD137 expression in tumor vessel walls. High correlation with malignant tumors., PMID:11293902 |
| Note | For research use only. Not suitable for clinical or therapeutic use. |
Detects Human CD137/TNFRSF9/4-1BB in indirect ELISAs.
7X24小时产品咨询热线：027--87433958(9:00-18:00)，或扫描下方产品专员二维码或在线留言
武汉东湖新技术开发区神墩四路666号研发楼B区3层东
24小时产品查询
扫一扫关注我们
专属渠道经理
